Athira Pharma Net Income
| ATHADelisted Stock | USD 4.74 0.09 1.94% |
As of the 5th of February, Athira Pharma shows the mean deviation of 4.12, and Risk Adjusted Performance of 0.0532. Athira Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Athira Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Athira Pharma's valuation are provided below:Athira Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Athira |
Athira Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Athira Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Athira Pharma.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Athira Pharma on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Athira Pharma or generate 0.0% return on investment in Athira Pharma over 90 days. Athira Pharma is related to or competes with Citius Pharmaceuticals, SeaStar Medical, Apollomics, Moleculin Biotech, Curis, FibroBiologics Common, and Lunai Bioworks. Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore n... More
Athira Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Athira Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Athira Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.49 | |||
| Information Ratio | 0.0526 | |||
| Maximum Drawdown | 71.83 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 6.7 |
Athira Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Athira Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Athira Pharma's standard deviation. In reality, there are many statistical measures that can use Athira Pharma historical prices to predict the future Athira Pharma's volatility.| Risk Adjusted Performance | 0.0532 | |||
| Jensen Alpha | 0.4473 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.1044 | |||
| Treynor Ratio | 0.3779 |
Athira Pharma February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0532 | |||
| Market Risk Adjusted Performance | 0.3879 | |||
| Mean Deviation | 4.12 | |||
| Semi Deviation | 4.1 | |||
| Downside Deviation | 4.49 | |||
| Coefficient Of Variation | 1669.93 | |||
| Standard Deviation | 8.9 | |||
| Variance | 79.12 | |||
| Information Ratio | 0.0526 | |||
| Jensen Alpha | 0.4473 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.1044 | |||
| Treynor Ratio | 0.3779 | |||
| Maximum Drawdown | 71.83 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 20.12 | |||
| Semi Variance | 16.79 | |||
| Expected Short fall | (4.91) | |||
| Skewness | 5.37 | |||
| Kurtosis | 36.57 |
Athira Pharma Backtested Returns
Athira Pharma appears to be very risky, given 3 months investment horizon. Athira Pharma secures Sharpe Ratio (or Efficiency) of 0.0731, which signifies that the company had a 0.0731 % return per unit of standard deviation over the last 3 months. By analyzing Athira Pharma's technical indicators, you can evaluate if the expected return of 0.68% is justified by implied risk. Please makes use of Athira Pharma's mean deviation of 4.12, and Risk Adjusted Performance of 0.0532 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Athira Pharma holds a performance score of 5. The firm shows a Beta (market volatility) of 1.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Athira Pharma will likely underperform. Please check Athira Pharma's maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to make a quick decision on whether Athira Pharma's price patterns will revert.
Auto-correlation | -0.1 |
Very weak reverse predictability
Athira Pharma has very weak reverse predictability. Overlapping area represents the amount of predictability between Athira Pharma time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Athira Pharma price movement. The serial correlation of -0.1 indicates that less than 10.0% of current Athira Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.1 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.95 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Athira Pharma reported net income of (96.94 Million). This is 128.4% lower than that of the Biotechnology sector and 238.4% lower than that of the Health Care industry. The net income for all United States stocks is 116.98% higher than that of the company.
Athira Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Athira Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Athira Pharma could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics of similar companies.Athira Pharma is currently under evaluation in net income category among its peers.
Athira Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.42 | |||
| Current Valuation | 2.31 M | |||
| Shares Outstanding | 3.94 M | |||
| Shares Owned By Insiders | 13.36 % | |||
| Shares Owned By Institutions | 85.51 % | |||
| Number Of Shares Shorted | 7.03 K | |||
| Price To Book | 0.99 X | |||
| EBITDA | (95.81 M) | |||
| Net Income | (96.94 M) | |||
| Cash And Equivalents | 252.4 M | |||
| Cash Per Share | 6.67 X | |||
| Total Debt | 1.22 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 26.40 X | |||
| Book Value Per Share | 6.79 X | |||
| Cash Flow From Operations | (97.17 M) | |||
| Short Ratio | 0.37 X | |||
| Earnings Per Share | (9.67) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 26 | |||
| Beta | 2.8 | |||
| Market Capitalization | 26.62 M | |||
| Total Asset | 58.78 M | |||
| Retained Earnings | (406.15 M) | |||
| Working Capital | 41.71 M | |||
| Net Asset | 58.78 M |
About Athira Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Athira Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Athira Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Athira Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Athira Stock
If you are still planning to invest in Athira Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Athira Pharma's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |